A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

A Phase 1 Open-label, 2-Period Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants

The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.

Inclusion Criteria:

• Healthy participants, defined as having no clinically significant deviations from normal in medical history
• Weight ≥ 50 kg and body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive, at screening
• Normal renal function at screening

Exclusion Criteria:

• Any significant acute or chronic medical illness
• Current or recent gastrointestinal (GI) disease that could impact upon the absorption of study treatment
• Any major surgery within 4 weeks of study treatment administration
• Significant history of GI abnormalities

Other protocol-defined inclusion/exclusion criteria apply